AMSTERDAM: EHC and Croma-Pharma GmbH (Croma) have amended their business combination agreement, adjusting the enterprise value of Croma to €712.5 million from €850 million.

The changes involve transferring 20% of Sponsor Shares to EHC for cancellation and increasing the exercise price of 20% of Sponsor Warrants. The amendments aim to align stakeholder interests and attract new investors.

The transaction is subject to approval at EHC’s general meeting and other closing conditions. Upon completion, EHC will become Croma N.V., a public company. The adjustment offers enhanced return opportunities and a strong post-IPO performance, according to Dr. Cornelius Baur, CEO of EHC.